Pfizer Aktie News

Pfizer (PFE) remains a 'Hold' due to near-term headwinds, including a $1.5B patent cliff in 2026 and declining Covid-19 revenues. PFE's long-acting GLP-1 obesity program, bolstered by the Metsera acquisition, shows promise but lacks approval until at least 2028. Excluding Covid-19 products, PFE achieved 6% operational revenue growth in 2025, but total revenues declined 2% year-over-year.

What does a successful retirement look like? If it means financial security through steady income sources, then you can get there with the help of high-yield dividend stocks.

Despite an 8.2% forward yield, be careful with Perrigo, due to its value trap reputation. Yielding 6.7%, Pfizer is a strong choice among high-yield dividend stocks, given the company's post-COVID-19 catalysts.

Pfizer made one thing clear this week: It's officially back in the obesity race.

Investors love dividend stocks, especially those with dependable, high yields, because they provide a substantial passive income stream and offer significant total return potential.

February's top Large Cap Value (GASV) stocks offer 27.69% to 69.77% net gains by February 2027, based on analyst targets. Fourteen of twenty-nine 'safer' lowest-priced GASV 'dogs' are currently buyable, with ideal dividend-to-price ratios and positive free cash flow yields. Top ten GASV by yield are ideally priced, with dividends from $1K invested exceeding share prices; all are considered 'IDE...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company's supplemental Biologics License Application (sBLA) for HYMPAVZI® (marstacimab) to expand the approved indication to include the treatment of hemophilia A or B patients 6 years and older with inhibitors, and pediatric patien...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the launch of its program on TrumpRx, making innovative medicines more affordable and accessible to millions of Americans. Starting today, the program provides Americans a wide range of more than 30 medicines at a significant discount off list prices. This effort is part of Pfizer's broader landmark Most Favored Nation (MFN) agr...